Although mAbs are potent and highly specific PD-1 blockers, their clinical performance is constrained by three categories of limitation: immune-related toxicities and organ-specific safety concerns, pharmacokinetic and tissue-penetration barriers, and adaptive or microenvironmental resistance within the tumor and host immune system (41). This evidence concerns the gene PDCD1 and neoplasm.